OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

September 30th 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Dr. Reck on the Safety of Pembrolizumab in KEYNOTE-024 in Metastatic NSCLC

September 30th 2020

Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

September 30th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma

September 30th 2020

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

September 30th 2020

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Dr. Shah on the Rationale for the KEYNOTE-590 Trial in Esophageal Carcinoma

September 30th 2020

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in locally advanced or metastatic esophageal carcinoma.

Dr. Nguyen on Treatment Considerations in High-Risk Prostate Cancer

September 29th 2020

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Dr. Choudhury on the Designs of Key Trials in Nonmetastatic CRPC

September 29th 2020

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

Dr. Hussain on the Rationale to Target the DNA Repair Pathway in mCRPC

September 29th 2020

Maha Hussain, MD, FACP, FASCO, discusses the rationale for targeting the DNA repair pathway in metastatic castration-resistant prostate cancer.

Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma

September 29th 2020

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma

September 29th 2020

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

September 28th 2020

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Skarbnik on the Approval of Tazemetostat in Relapsed/Refractory Follicular Lymphoma

September 28th 2020

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Dr. Rampal on Challenges With Targeting High-Risk Mutations in Myelofibrosis

September 28th 2020

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL

September 28th 2020

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma

September 28th 2020

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma.

Dr. Azad on the Post-Hoc Analysis of the ARCHES Study in mHSPC

September 28th 2020

Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.

Dr. Petrylak on the Role of PSA Screening in Prostate Cancer

September 28th 2020

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Dr. Batlevi on Emerging Therapies in Follicular Lymphoma

September 25th 2020

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Dr. Skarbnik on the Utility of PI3K Inhibitors in Follicular Lymphoma

September 25th 2020

Alan P. Z. Skarbnik, discusses ongoing research with PI3K inhibitors in follicular lymphoma.